Axsome Therapeutics, Inc.
AXSM
$121.91
$0.260.21%
| Weiss Ratings | AXSM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | AXSM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Good | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | AXSM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.90 | |||
| Price History | AXSM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -2.01% | |||
| 30-Day Total Return | 14.51% | |||
| 60-Day Total Return | 35.94% | |||
| 90-Day Total Return | 37.22% | |||
| Year to Date Total Return | 39.61% | |||
| 1-Year Total Return | 61.38% | |||
| 2-Year Total Return | 96.85% | |||
| 3-Year Total Return | 318.50% | |||
| 5-Year Total Return | 183.91% | |||
| 52-Week High % Change | -12.38% | |||
| 52-Week Low % Change | 90.16% | |||
| Price | AXSM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $139.13 | |||
| 52-Week Low Price | $64.11 | |||
| 52-Week Low Price (Date) | Jun 11, 2024 | |||
| 52-Week High Price (Date) | Feb 21, 2025 | |||
| Valuation | AXSM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 5.94B | |||
| Enterprise Value | 5.82B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -6.00 | |||
| Earnings Per Share Growth | 15.29% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 15.34 | |||
| Price/Book (Q) | 104.06 | |||
| Enterprise Value/Revenue (TTM) | 15.10 | |||
| Price | $121.91 | |||
| Enterprise Value/EBITDA (TTM) | -23.82 | |||
| Enterprise Value/EBIT | -23.07 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | AXSM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 48.54M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AXSM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | (212) 332-3241 | |||
| Address | One World Trade Center New York, NY 10007 | |||
| Website | www.axsome.com | |||
| Country | United States | |||
| Year Founded | 2012 | |||
| Profitability | AXSM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -65.45% | |||
| Profit Margin | -74.46% | |||
| Management Effectiveness | AXSM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -27.28% | |||
| Return on Equity | -- | |||
| Income Statement | AXSM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 385.69M | |||
| Total Revenue (TTM) | 385.69M | |||
| Revenue Per Share | $7.95 | |||
| Gross Profit (TTM) | 352.39M | |||
| EBITDA (TTM) | -244.48M | |||
| EBIT (TTM) | -252.44M | |||
| Net Income (TTM) | -287.22M | |||
| Net Income Avl. to Common (TTM) | -287.22M | |||
| Total Revenue Growth (Q YOY) | 66.04% | |||
| Earnings Growth (Q YOY) | 24.06% | |||
| EPS Diluted (TTM) | -6.00 | |||
| EPS Diluted Growth (Q YOY) | 25.96% | |||
| Balance Sheet | AXSM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 315.35M | |||
| Cash Per Share (Q) | $6.50 | |||
| Total Current Assets (Q) | 485.06M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 57.02M | |||
| Current Ratio (Q) | 2.108 | |||
| Book Value Per Share (Q) | $1.17 | |||
| Total Assets (Q) | 568.50M | |||
| Total Current Liabilities (Q) | 230.10M | |||
| Total Debt (Q) | 192.96M | |||
| Total Liabilities (Q) | 511.48M | |||
| Total Common Equity (Q) | 57.02M | |||
| Cash Flow | AXSM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -270.00K | |||
| Cash from Financing (TTM) | 57.84M | |||
| Net Change in Cash (TTM) | -70.84M | |||
| Levered Free Cash Flow (TTM) | -28.71M | |||
| Cash from Operations (TTM) | -128.41M | |||
